Till startsida
University of Gothenburg
To content Read more about how we use cookies on gu.se

Group Anders Ståhlberg

Research summary

Our research is focused on human sarcomas caused by FET (FUS, EWSR1, TAF15) fusion oncogenes and breast cancer. We are particular interested in understanding cell fate mechanisms between cancer stem cells, proliferating cell and therapy resistant cells.

Tumor cells have a remarkable ability to respond to internal and external stimuli in a specific manner. Yet, tumor cells are in many aspects unique in their characteristics also within a seemingly homogenous population. Recent development of single-cell and single-molecule techniques opens up new avenues to investigate tumor heterogeneity and the dynamic transition between cell states.

Another focus is to develop diagnostic tools enabling precision medicine. To date it has been challenging to monitor treatment and potential relapse in cancer, but analysis of circulating cell-free tumor DNA in liquid biopsies opens up new means to address this issue. However, standard next-generation sequencing suffer from insufficient sensitivity. Hence, we have developed SiMSen-Seq that allows ultrasensitive mutant detection.

In the short-term perspective we expect that our research will reveal fundamental information about tumor origin, tumor cell diversity and deeper understanding of molecular mechanisms in sarcoma and breast cancer development. Ultimately, this will contribute to the development of novel treatment paradigms and a more precise diagnosis and prognosis of cancer patients.

Specific projects include:

  • To define tumor cell hierarchy and to determine key cell fate decisions.
  • Functional single-cell analysis.
  • To define biological processes behind tumor drug resistance.
  • To determine the role of microenvironment in relation to cell types.
  • Development of tumor bioreactors for next generation drug test systems, including 3D bioprinting.
  • Development and evaluation of non-invasive methods in cancer diagnostics, including ultrasensitive mutation detection using circulating cell-free tumor DNA.
  • Diagnostics using circulating cell-free DNA and clinical implementation.

Research tools and resources

We use several single-cell and single-molecule techniques to study tumor biology, including qPCR, PLA and NGS. In addition to clinical samples, we also use stem cells, tumor cell lines, reporter cell lines, primary cells and mouse xenografts as model systems. We work closely with the Translational Genomics Platform.

Current group members

Anders Ståhlberg, PhD, Associate Professor
Daniel Andersson, Postdoc
Soheila Dolatabadi, Postdoc
Parmida Ranji, Postdoc
Helena Kristiansson, PhD, Biologist
Tobias Österlund, PhD, Bioinformatician
Amin Forootan, PhD student
Emma Jonasson, PhD student
Stefan Filges, PhD student
Gustav Johansson, PhD student (with AstraZeneca)
Mahnaz Irani Shemirani, PhD student (with Skövde Högskola)
Junrui Li, MSc, Lab engineer
Melita Kaltak, Lab engineer
Jennifer Pettersson, associated PhD student
Emma Persson, associated PhD student
Christoffer Vannas, associated PhD student
Cristiana Rimniceanu, associated PhD student
Malin Nilsson, associated PhD student
Anna Gustafsson, associated PhD student
Karoline Berger, associated PhD student
Malin Lindén, associated PhD student
Hana Komic, associated PhD student
Peter Micallef, associated PhD student
Elisabeth Mellström, associated PhD student

We have openings for MSc thesis projects.

Recent selected publications

  1. JAK-STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma.
    Dolatabadi S, Jonasson E, Lindén M, Fereydouni B, Bäcksten K, Nilsson M, Martner A, Forootan A, Fagman H, G Landberg, Åman P, Ståhlberg A. International Journal of Cancer, 2019, doi:10.1002/ijc.32123. PMID: 30650179
  2. Considerations and quality controls when analyzing cell-free tumor DNA.
    Johansson G, Andersson D, Filges S, Li J, Muth A, Godfrey TE, Ståhlberg, A. Biomolecular Detection and Quantification, 2019, doi.org/10.1016/j.bdq.2018.12.003
  3. Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxiod liposarcoma using combined DNA, mRNA and protein analyzes.
    Svec D, Dolatabadi S, Thomsen C, Cordes N, Shannon M, Fitzpatrick P, Landberg G, Åman P, Ståhlberg A. Laboratory Investigation, 2018, 98:957-67.
  4. Technical aspects and recommendations for single-cell qPCR. Ståhlberg A., Kubista M. Molecular Aspects of Medicine, 2018, 59:28-35.
  5. Transcriptomic characterization of the human cell cycle in individual unsynchronized cells.
    Karlsson J, Kroneis T, Jonasson E, Larsson E, Ståhlberg A.  Journal of Molecular Biology, 2017, 429:3909-24.
  6. Simple multiplexed PCR-based barcoding of DNA for ultrasensitive mutation detection by next-generation sequencing.
    Ståhlberg A., Krzyzanowski PM, Egyud M, Filges S, Stein L, Godfrey TE. Nature Protocols, 2017, 12:664-82.


More group Anders Ståhlberg publications on PubMed

Translational Genomics Platform

Read more about Translational Genomics Platform and its activities.

Contact information

Anders Ståhlberg

E-mail: Anders Ståhlberg
Phone: +46 (0)31 786 6735

Visiting address:
Sahlgrenska Cancer Center
Medicinaregatan 1F
413 90 Gothenburg

Page Manager: Yael Zukovsky Fitoussi|Last update: 2/28/2019

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?